Delving into the Latest Updates on pSG2.HIVconsv(University of Oxford) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine

Synonyms-

Target-

Action

stimulants

Mechanism

Immunostimulants

Therapeutic Areas

Immune System DiseasesInfectious DiseasesUrogenital Diseases

Active Indication

HIV Infections

Inactive Indication

Acquired Immunodeficiency Syndrome

Originator Organization

University of Oxford

Active Organization

University of Oxford

Inactive Organization

Ichor Medical Systems, Inc.

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The study is part of a long-term aim to develop an effective HIV-1 vaccine and will evaluate safety and immunogenicity of vaccines focusing T cell responses on the conserved region of the HIV-1 proteome. The vaccines used are pSG2.HIVconsv DNA (D), MVA.HIVconsv (M) and Ad35-GRIN (A), delivered in regimens AM, DDDAM and DeDeDeAM, where e indicates electroporation.

Start Date01 Mar 2014

Sponsor / Collaborator

University of Oxford

[+4]

NCT02425241

/ CompletedPhase 1/2IIT

A Randomised Double-blind, Placebo-controlled Phase I/IIa Trial to Investigate the Effect of Depletion of Serum Amyloid P Component (SAP) on the Immune Response to DNA Vaccination in Healthy Male Volunteers

This is a clinical proof-of-concept (PoC) study of DNA vaccination after SAP depletion. The investigators will measure the immune responses to DNA vaccination against HIV-1 in healthy adult male volunteers, comparing a group in whom SAP has been completely depleted at the time of DNA vaccination and a control group vaccinated without SAP depletion.

Start Date01 Oct 2013

Sponsor / Collaborator

University College London

[+3]

100 Clinical Results associated with pSG2.HIVconsv(University of Oxford)

Login to view more data

100 Translational Medicine associated with pSG2.HIVconsv(University of Oxford)

Login to view more data

100 Patents (Medical) associated with pSG2.HIVconsv(University of Oxford)

Login to view more data

100 Deals associated with pSG2.HIVconsv(University of Oxford)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acquired Immunodeficiency Syndrome	Phase 2	Kenya	Ichor Medical Systems, Inc.	01 Mar 2014
HIV Infections	Phase 1	Zambia	University of Oxford	30 Jan 2022
HIV Infections	Phase 1	Uganda	University of Oxford	30 Jan 2022
HIV Infections	Phase 1	Kenya	University of Oxford	30 Jan 2022